Novel polymorphs of 6-(cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide

The novel polymorphs of Deucravacitinib: adipic acid, characterized by distinct X-ray diffraction patterns, address solubility and stability challenges, achieving superior solubility and stability for improved clinical efficacy.

WO2024241347A1PCT designated stage expired Publication Date: 2024-11-28MSN LABORATORIES PRIVATE LIMITED +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2024/050610
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Deucravacitinib, a selective allosteric tyrosine kinase 2 (TYK2) inhibitor, faces challenges with solubility and stability due to its polymorphic forms, which affect its pharmaceutical properties such as solubility profiles, melting points, and x-ray diffraction peaks, necessitating the identification of stable and soluble forms for effective clinical use.

Method used

The development of novel polymorphs, specifically crystalline Form-M and Form-S of Deucravacitinib: adipic acid, characterized by distinct X-ray powder diffraction patterns, which are prepared using solvents like ketones, alcohols, and chloro solvents, and processed to enhance solubility and stability, offering superior solubility and stability compared to existing forms.

Benefits of technology

The novel polymorphs demonstrate improved solubility and stability, addressing the limitations of previous forms, with crystalline Form-M and Form-S exhibiting enhanced pharmaceutical properties suitable for clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IN2024050610_28112024_PF_FP_ABST
    Figure IN2024050610_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel polymorphs of 6- (cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N- (trideuteriomethyl)pyridazine-3-carboxamide and its preparation processes. The present invention also relates to an improved process for the preparation of Deucravacitinib of formula-1.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Novel polymorphs of 6-(cycloDroDanecarbonylamido)-4-[2-methoxy-3-(l-methyl-l.,2.,4- triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide

[0002] Related Application:

[0003] This application claims the benefit of priority of our Indian patent application number 202341036310 filed on 25thMay 2023 which are incorporated herein by reference.

[0004] Field of the Invention:

[0005] The present invention relates to a novel polymorphs of 6- (cyclopropanecarbonylamido)-4-[2-methoxy-3-(l -methyl- 1,2, 4-triazol-3-yl)anilino]-N- (trideuteriomethyl)pyridazine-3-carboxamide compound of formula- 1 and process for its preparation.

[0006] Formula-1

[0007] The present invention also relates to an improved process for the preparation of Deucravacitinib of formula- 1.

[0008] Background of the Invention:

[0009] Deucravacitinib is chemically known as 6-(cyclopropanecarbonylamido)-4-[2- methoxy-3-(l-methyl-l,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3- carboxamide.

[0010] Deucravacitinib is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first and only selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Deucravacitinib is being evaluated in global clinical trials in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel diseases. Deucravacitinib is under regulatory review with global health authorities. Deucravacitinib was approved for medical use in the United States in September 2022. US 9505748B2 and US 10899745B2 discloses the Deucravacitinib and its preparation process.

[0011] US2020239449A1 describes the crystalline Form-A of Deucravacitinib and its preparation processes.

[0012] US20220259183A1 describes the crystalline Form-E of Deucravacitinib and its preparation processes.

[0013] WO2021055651 Al describes the amorphous form of Deucravacitinib.

[0014] Polymorphism is the occurrence of different crystalline forms of a single compound and it is a property of some compounds and complexes. Thus, polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct physical properties. Therefore, a single compound may give rise to a variety of polymorphic forms where each form has different and distinct physical properties, such as different solubility profiles, different melting point temperatures and / or different x-ray diffraction peaks. Since the solubility of each polymorph may vary, identifying the existence of pharmaceutical polymorphs is essential for providing pharmaceuticals with predicable solubility profiles. It is desirable to investigate all solid state forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form.

[0015] Polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy and by other methods such as, infrared spectrometry. Additionally, polymorphic forms of the same drug substance or active pharmaceutical ingredient, can be administered by itself or formulated as a drug product (also known as the final or finished dosage form), and are well known in the pharmaceutical art to affect, for example, the solubility, stability, flowability, tractability and compressibility of drug substances.

[0016] Brief description of the Invention:

[0017] The present invention relates to a novel polymorph of Deucravacitinib:Adipic acid and Deucravacitinib of formula- 1 and its preparation processes.

[0018] The present invention also relates to an improved process for the preparation of Deucravacitinib of formula- 1.

[0019] Brief description of the Drawings:

[0020] Figure-1: Illustrates the PXRD pattern of crystalline Form-M of Deucravacitinib:Adipic acid.

[0021] Figure-2: Illustrates the PXRD pattern of crystalline Form-S of Deucravacitinib. Detailed description of the Invention:

[0022] As used herein the term “suitable solvent” used in the present invention refers to “hydrocarbon solvents” such as n-hexane, n-heptane, cyclohexane, pet ether, toluene, pentane, cycloheptane, methyl cyclohexane, m-, o-, or p-xylene, and the like; “ether solvents” such as dimethoxy methane, tetrahydrofuran, 1,3 -dioxane, 1,4-di oxane, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, dimethoxy ethane and the like; “ester solvents” such as methyl acetate, ethyl acetate, isopropyl acetate, n- butyl acetate and the like; “polar-aprotic solvents such as dimethylacetamide (DMA), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP) and the like; “chloro solvents” such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like; “ketone solvents” such as acetone, methyl ethyl ketone, methyl isobutylketone and the like; “nitrile solvents” such as acetonitrile, propionitrile, isobutyro nitrile and the like; “alcoholic solvents” such as methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutanol, t-butanol, 2-nitroethanol, 2 -fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 2-methoxyethanol, 1, 2-ethoxyethanol, diethylene glycol, 1, 2, or 3-pentanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol, monoethyl ether, cyclohexanol, benzyl alcohol or glycerol and the like; “polar solvents” such as water or mixtures thereof.

[0023] The “suitable base” as used in the present invention is selected from inorganic bases like “alkali metal hydroxides” such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; “alkali metal carbonates” such as sodium carbonate, potassium carbonate, lithium carbonate and the like; “alkali metal bicarbonates” such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate and the like; “alkali metal hydrides” such as sodium hydride, potassium hydride, lithium hydride and the like; ammonia; and organic bases such as “alkali metal alkoxides” such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide and the like; triethyl amine, methyl amine, ethylamine, 1,8-diaza bicyclo[5.4.0]undec-7-ene (DBU), 1,5- diazabicyclo(4.3.0)non-5-ene (DBN), lithiumdiiso propylamide (LDA), n-butyl lithium, tribenzylamine, isopropyl amine, diisopropylamine, diisopropylethylamine, N- methylmorpholine, N-ethylmorpholine, piperidine, dimethylamino pyridine, morpholine, pyridine, 2,6-lutidine, 2,4,6-collidine, imidazole, 1-methyl imidazole, 1,2,4-triazole, 1,4- diazabicyclo[2.2.2]octane (DABCO) or mixtures thereof. In the first embodiment, the present invention provides a crystalline Form-M of Deucravacitinib : Adipic acid.

[0024] The first aspect of the first embodiment provides crystalline Form-M of Deucravacitinib Adipic acid, which is characterized by its X-ray powder diffraction (XRD) pattern having peaks at about 7.1, 9.3 and 20.8 ± 0.2 degrees 2-theta.

[0025] The second aspect of the first embodiment provides crystalline Form-M of Deucravacitinib Adipic acid, further characterized by its X-ray powder diffraction (XRD) pattern having peaks at about 6.2, 13.6, 21.5 and 23.3 ± 0.2 degrees 2-theta.

[0026] The third aspect of the first embodiment provides crystalline Form-M of Deucravacitinib Adipic acid characterized by its powder X-Ray diffraction (XRD) pattern as illustrated in figure-1.

[0027] In the second embodiment, the present invention provides a process for the preparation of crystalline Form-M of Deucravacitinib Adipic acid, comprising: a) providing a solution of Deucravacitinib and Adipic acid in a solvent, b) isolating crystalline Form-M of Deucravacitinib and Adipic acid.

[0028] In step-a) of the second embodiment, the solvent is selected from ketone solvent, alcohol solvent, chloro solvent or mixtures thereof.

[0029] In the process of second embodiment, providing a solution of Deucravacitinib and Adipic acid of step-a) comprises dissolving Deucravacitinib and Adipic acid in a solvent. Optionally filtering the mixture to make it particle free.

[0030] In an embodiment, the present invention crystalline form-M of Deucravacitinib: adipic acid may be a co-crystal or any other solid state form comprising Deucravacitinib and adipic acid.

[0031] The solubility of a drug is an imperative factor which needs to be considered during the development. As per the developmental data, Deucravacitiib is a weak base, and the drug substance may fall under Biopharmaceutical Classification System of class-2 due to high permeability and limited solubility.

[0032] To overcome the solubility issue, the inventors of the present invention have used several approaches, in which the crystalline Form-M of Deucravacitinib:adipic acid found to have superior solubility compared to the other existing crystalline forms such as Deucravacitiib crystalline form-A, Deucravacitiib Crystalline Form-E or Deucravacitiib amorphous form. Below tabular summary represents the solubility comparative data between crystalline

[0033] Form-M of Deucravacitinib: adipic acid and Deucravacitiib crystalline form-A, Deucravacitiib Crystalline Form-E or Deucravacitiib amorphous form.

[0034] In addition to the above solubility advantage, the crystalline form-M of Deucravacitinib:adipic acid is found to be stable in several conditions.

[0035] Below is the tabular summary of stability under different conditions:

[0036] In the third embodiment, the present invention provides a crystalline Form-S of Deucravacitinib. The first aspect of the third embodiment provides crystalline Form-S of Deucravacitinib, which is characterized by its X-ray powder diffraction (XRD) pattern having peaks at about 7.0 and 23.2 ± 0.2 degrees 2-theta.

[0037] The second aspect of the third embodiment provides crystalline Form-S of Deucravacitinib, which is further characterized by its X-ray powder diffraction (XRD) pattern having peaks at about 9.2, 15.0, 20.0 and 20.7 ± 0.2 degrees 2-theta.

[0038] The third aspect of the third embodiment provides crystalline Form-S of Deucravacitinib characterized by its powder X-Ray diffraction (XRD) pattern as illustrated in figure-2.

[0039] In the fourth embodiment, the present invention provides a process for the preparation of crystalline Form-S of Deucravacitinib, comprising: a) providing a solution of Deucravacitinib in a solvent, b) isolating crystalline Form-S of Deucravacitinib.

[0040] In step-a) of the fourth embodiment, the solvent is selected from chloro solvent, ketone solvent, ether solvent or mixtures thereof.

[0041] In the fifth embodiment, the present invention provides an improved process for the preparation of Deucravacitinib comprising one or more reaction steps of the following synthetic scheme.

[0042]

[0043] Formula- 1 Deucravacitinib wherein X is F, Cl, Br or I

[0044] In the sixth embodiment, the present invention provides novel intermediate compound of Deucravacitinib of formula- 1 represented by the following structural formula.

[0045] The above mentioned novel intermediate compound is useful in the preparation of Deucravacitinib of formula-1.

[0046] In the process of the present invention, Deucravacitinib or Deucravacitinib: Adipic acid crystalline Form-M or Deucravacitinib crystalline Form-S can be isolated by removal of solvent, which is carried out by suitable techniques including but not limited to decantation, evaporation under reduced pressure, flash evaporation, vacuum drying, concentrating the reaction mixture, atmospheric distillation, distillation under reduced pressure, distillation by using a rotational distillation device such as buchi rotavapor, agitated thin film drying (ATFD), melt extrusion, spray drying, freeze drying (lyophilization), spray-freeze drying, cooling the clear solution to lower temperatures to precipitate the solid followed by filtration of the reaction mixture or by any other suitable techniques known in the art.

[0047] In the process of the present invention, Deucravacitinib or Deucravacitinib: Adipic acid crystalline Form-M or Deucravacitinib crystalline Form-S can be dried in suitable drying equipment such as tray dryer, vacuum oven, rotatory cone dryer, air oven, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying can be carried out at atmospheric pressure or under reduced pressure at temperature of less than about 100°C, less than about 60°C, less than about 40°C, or any other suitable temperature. The drying can be carried out for any time period required for obtaining a desired quality such as from about 15 minutes to about 10 hours or longer.

[0048] In the process of the present invention, Deucravacitinib or Deucravacitinib: Adipic acid crystalline Form-M or Deucravacitinib crystalline Form-S can be further micronized or milled to get desired particle size to achieve desired solubility profile based on different forms of pharmaceutical composition requirements. Techniques that can be used for particle size reduction include but not limited to single or multi-stage micronization using cutting mills, pin / cage mills, hammer mills, jet mills, fluidized bed jet mills, ball mills and roller mills. Milling or micronization can be performed before drying or after drying of the product.

[0049] In an embodiment, the present invention provides pharmaceutical composition comprising Deucravacitinib or ‘Deucravacitinib: Adipic acid’ crystalline Form-M or Deucravacitinib crystalline Form-S and one or more pharmaceutically acceptable excipients.

[0050] The excipients can be selected from Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems 2006.

[0051] In an embodiment, crystalline form-M of ‘Deucravacitinib: Adipic acid’ or crystalline Form-S of Deucravacitinib, prepared according to the present invention is having purity of about 99.9%; preferably about 99.95%; more preferably about 99.97% as measured by HPLC.

[0052] In another embodiment, a pharmaceutical composition comprising Deucravacitinib or ‘Deucravacitinib Adipic acid’ crystalline Form-M or Deucravacitinib crystalline Form-S and one or more pharmaceutically acceptable excipients is formulated in a manner suitable for the route of administration to be used. As used herein, the term "pharmaceutical compositions" include tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection preparations.

[0053] The Deucravacitinib, used as an input in carrying out the present invention can be obtained from the synthetic process described by the present invention or any of the processes known in the art.

[0054] P-XRD Method of Analysis:

[0055] PXRD analysis of present invention is carried out by using BRUKER / D8 ADVANCE diffractometer using Cu Ka radiation of wavelength 1.5406 A0and continuous scan speed of 0.037min.

[0056] The process described in the present invention is demonstrated in examples illustrated below. These examples are provided as illustration only and therefore should not be construed as limitation of the scope of the invention.

[0057] Examples:

[0058] Example-1: Preparation of crystalline Form-M of Deucravacitinib: Adipic acid

[0059] Deucravacitinib (200 mg) and adipic acid (68 mg) were added to morter. Acetone (2 ml) was added to the mixture at 25-30°C. Ground the mixture for 30 minutes and dried the mixture to get title compound.

[0060] Yield: 205 mg.

[0061] The obtained compound was characterized by the PXRD pattern as illustrated in figure- 1.

[0062] Example-2: Preparation of crystalline Form-M of Deucravacitinib: Adipic acid

[0063] Amixture of methanol (1.5 ml) and dichloromethane (1.5 ml) were added to the mixture of Deucravacitinib (100 mg) and adipic acid (28 mg) at 25-30°C. Stirred the mixture for 2 hrs at 25-30°C. Filtered the mixture and dried to get the title compound.

[0064] Yield: 90 mg.

[0065] The obtained compound was characterized by the PXRD pattern as illustrated in figure- 1.

[0066] Example-3: Preparation of crystalline Form-M of Deucravacitinib: Adipic acid

[0067] Amixture of methanol (11 ml) and dichloromethane (11 ml) were added to the mixture of Deucravacitinib (500 mg) and adipic acid (171 mg) at 25-30°C. Stirred the mixture for 20 minutes at 25-30°C. Filtered the mixture to get particle free solution. Distilled-off the solvent and dried to get the title compound.

[0068] Yield: 514 mg. The obtained compound was characterized by the PXRD pattern as illustrated in figure- 1.

[0069] Example-4: Preparation of crystalline Form-S of Deucravacitinib

[0070] Chloroform (48 ml) was added to Deucravacitinib (1 gm) at 25-30°C. Heated the mixture at 60-65°C and filtered the mixture to make it particle free. Cooled the mixture to 25- 30°C. Reaction mixture added to cyclohexanone (50 ml) and methyl tert-butyl ether (50 ml) solvent mixture at 25-30°C. Stirred the mixture for 3 hrs at 25-30°C. Filtered the mixture to get title compound.

[0071] Yield: 781 mg

[0072] The obtained compound was characterized by the PXRD pattern as illustrated in figure-2. Example-5: Preparation of crystalline Form-M of Deucravacitinib: Adipic acid

[0073] A mixture of methanol (110 ml) and dichloromethane (110 ml) were added to the mixture of Deucravacitinib (5 g) and adipic acid (860 mg) at 25-30°C. Stirred the mixture for 15 minutes at 25-30°C. Filtered the mixture to get particle free solution. Distilled-off the solvent and dried to get the title compound. Yield: 4.2 g

[0074] The obtained compound was characterized by the PXRD pattern as illustrated in figure- 1.

Claims

We Claim:

1. Crystalline form-M of Deucravacitinib: Adipic acid.

2. The Crystalline Form-M of Deucravacitinib: Adipic acid as claimed in claim 1, characterized by one or more of the following characteristics:(i) PXRD (Powder X-Ray diffraction) pattern having peaks at about 7.1°, 9.3° and 20.8° ± 0.2° 26, or(ii) PXRD (Powder X-Ray diffraction) pattern having peaks at about 6.2°, 13.6°, 21.5° and 23.3° ± 0.2° 29, or(iii) PXRD pattern as illustrated in figure- 1.

3. A process for the preparation of Crystalline Form-M of Deucravacitinib: Adipic acid, comprising: a) providing a solution of Deucravacitinib and Adipic acid in a solvent, b) isolating Crystalline Form-M of Deucravacitinib:Adipic acid.

4. The process as claimed in claim 3, wherein the solvent in step-a) is selected from ketone solvent, alcohol solvent, chloro solvent or mixtures thereof.

5. Crystalline Form-S of Deucravacitinib, characterized by its X-ray powder diffraction (XRD) pattern having peaks at about 7.0 and 23.2 ± 0.2 degrees of 2 -theta.

6. The Crystalline Form-S of Deucravacitinib as claimed in claim 5, is further characterized by its Powder X-Ray diffraction pattern having peaks at 9.2, 15.0, 20.0 and 20.7 ± 0.2° of 2-theta.

7. Crystalline Form-S of Deucravacitinib as claimed in claim 5, is further characterized by its PXRD (powder X-Ray diffractogram) pattern substantially in accordance with figure 2.

8. A process for the preparation of Crystalline Form-S of Deucravacitinib, comprising: a) providing a solution of Deucravacitinib in a solvent, b) isolating Crystalline Form-S of Deucravacitinib.

9. The process as claimed in claim 8, wherein the solvent in step-a) is selected from chloro solvent, ketone solvent, ether solvent or mixtures thereof.

10. A pharmaceutical composition comprising the Crystalline form-M of Deucravacitinib:Adipic acid of claim 1 and one or more pharmaceutically acceptable excipients.

11. A pharmaceutical composition comprising the Crystalline Form-S of Deucravacitinib of claim 5 and one or more pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Salts of pyridazine derivative, crystal forms thereof, and preparation method and application of the salts

    CN113968846A

  • Deucravacitinib crystal form, preparation method therefor and use thereof

    US20230049130A1

  • Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-YL)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

    WO2023023322A1